Evidence map›Paper›PMID 35058313›Full record

ArticleBMJ open diabetes research & care2022

Plasma advanced glycation end products and the subsequent risk of microvascular complications in type 1 diabetes in the DCCT/EDIC.

Vincent M Monnier, David R Sell, Xiaoyu Gao, Saul M Genuth, John M Lachin, Ionut Bebu, DCCT/EDIC Research Group

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open diabetes research & care, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
3.9field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Musculoskeletal complications in patients with diabetes mellitus.The Korean journal of internal medicine · 2022
    Review
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Vincent M MonnierPathology and Biochemistry, Case Western Reserve University Department of Pathology, Cleveland, Ohio, USA vmm3@cwru.edu ibebu@bsc.gwu.edu.ORCID 0000-0002-4894-3142
David R SellPathology, Case Western Reserve University, Cleveland, Ohio, USA.
Xiaoyu GaoThe Biostatistics Center, The George Washington University, Rockville, Maryland, USA.
Saul M GenuthMedicine, Case Western Reserve University, Cleveland, Ohio, USA.
John M LachinThe Biostatistics Center, The George Washington University, Rockville, Maryland, USA.ORCID 0000-0001-9838-2841
Ionut BebuThe Biostatistics Center, The George Washington University, Rockville, Maryland, USA vmm3@cwru.edu ibebu@bsc.gwu.edu.ORCID 0000-0002-4944-7968
DCCT/EDIC Research Group
Case Western Reserve University · USGeorge Washington University · US

Funding

Limited Competition for the Continuation of Epidemiology of Diabetes Interventions and Complications (EDIC) Study Clinical Research Center (Collaborative U01)U01DK094157 · NIDDK · CASE WESTERN RESERVE UNIVERSITY · PI Ionut Bebu, Barbara Halina Braffett · 2011 to 2026
$97.6M
Epidemiology of Diabetes Interventions and Complications Data Coordinating CenterU01DK094176 · NIDDK · GEORGE WASHINGTON UNIVERSITY · PI BEBU, IONUT, BRAFFETT, BARBARA HALINA · 2012 to 2022
$30.8M
Metabolic Markers of Carbonyl, Oxidative and Nitrosative Stress in the DCCT/EDICDP3DK101123 · NIDDK · CASE WESTERN RESERVE UNIVERSITY · PI CLEARY, PATRICIA ANN, MONNIER, VINCENT M · 2013 to 2013
$1.1M
NIDDK NIH HHS DP3 DK101123NIDDK NIH HHS U01 DK094157NIDDK NIH HHS U01 DK094176
6 · The paper itself

Abstract

introductionTo assess impact of glycemic control on plasma protein-bound advanced glycation end products (pAGEs) and their association with subsequent microvascular disease. RESEARCH DESIGN AND

methodsEleven pAGEs were measured by liquid chromatography-mass spectrometry in banked plasma from 466 participants in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study at three time points (TPs): DCCT year 4 (TP1) and year 8 (TP2) and EDIC year 5/6 (TP3). Correlation coefficients assessed cross-sectional associations, and Cox proportional hazards models assessed associations with subsequent risk of microvascular complications through EDIC year 24.

resultsGlucose-derived glycation products fructose-lysine (FL), glucosepane (GSPN) and carboxymethyl-lysine (CML) decreased with intensive glycemic control at both TP1 and TP2 (p<0.0001) but were similar at TP3, and correlated with hemoglobin A1c (HbA1c). At TP1, the markers were associated with the subsequent risk of several microvascular outcomes. These associations did not remain significant after adjustment for HbA1c, except methionine sulfoxide (MetSOX), which remained associated with diabetic kidney disease. In unadjusted models using all 3 TPs, glucose-derived pAGEs were associated with subsequent risk of proliferative diabetic retinopathy (PDR, p<0.003), clinically significant macular edema (CSME, p<0.015) and confirmed clinical neuropathy (CCN, p<0.018, except CML, not significant (NS)). Adjusted for age, sex, body mass index, diabetes duration and mean updated HbA1c, the associations remained significant for PDR (FL: p<0.002, GSPN: p≤0.02, CML: p<0.003, pentosidine: p<0.02), CMSE (CML: p<0.03), albuminuria (FL: p<0.02, CML: p<0.03) and CCN (FL: p<0.005, GSPN : p<0.003).

conclusionspAGEs at TP1 are not superior to HbA1c for risk prediction, but glucose-derived pAGEs at three TPs and MetSOX remain robustly associated with progression of microvascular complications in type 1 diabetes even after adjustment for HbA1c and other factors.

Indexed as

Diabetes Mellitus, Type 1Diabetic RetinopathyCross-Sectional StudiesGlycated HemoglobinGlycation End Products, AdvancedHumansGlycated HemoglobinGlycation End Products, Advanceddiabetic neuropathiesglycated hemoglobin Akidneyoxidative stress

Identifiers

PMID35058313
PMCPMC8783825
OpenAlexW4205239800

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.